Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,006,702 | 115,077 | 174,927 | 139,376 | 67,669 |
| Marketable Securities | 364,038 | 676,479 | 581,386 | 537,562 | 177,351 |
| Receivables | 69,922 | 54,798 | 61,047 | 58,096 | 52,392 |
| Inventories | 10,263 | 13,266 | 9,126 | 11,900 | 15,489 |
| Other current assets | 6,191 | 5,795 | 5,785 | 6,986 | 40,044 |
| TOTAL | $1,457,116 | $865,415 | $832,271 | $753,920 | $352,945 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | 3,466 | 3,632 |
| Investments And Advances | 156,873 | 312,821 | 167,951 | 355,053 | 10,908 |
| Intangibles | 310,785 | 318,882 | 326,979 | 335,076 | 351,674 |
| Other Non-Current Assets | 261,101 | 34,987 | 233,436 | 29,257 | 229,445 |
| TOTAL | $728,759 | $666,690 | $728,366 | $722,852 | $595,659 |
| Total Assets | $2,185,875 | $1,532,105 | $1,560,637 | $1,476,772 | $948,604 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,405 | 5,264 | 3,238 | 3,679 | 8,584 |
| Accrued Expenses | 31,867 | 31,845 | 31,453 | 24,084 | 17,464 |
| Other current liabilities | 1,165 | 577 | 422 | 403 | 37,157 |
| TOTAL | $46,736 | $40,667 | $37,447 | $30,539 | $64,734 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | N/A | 111 |
| Other Non-Current Liabilities | 1,149,969 | 471,502 | 469,959 | 473,389 | 23,095 |
| TOTAL | $1,171,623 | $494,116 | $505,978 | $496,062 | $55,341 |
| Total Liabilities | $1,218,359 | $534,783 | $543,425 | $526,601 | $120,075 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 19,936 | 20,041 | 19,941 | 19,682 | 19,597 |
| Common Shares | 20 | 20 | 20 | 20 | 20 |
| Retained earnings | 583,251 | 594,743 | 608,088 | 578,215 | 461,380 |
| Other shareholders' equity | 4,476 | 5,390 | 8,455 | 9,322 | 8,494 |
| TOTAL | $967,516 | $997,322 | $1,017,212 | $950,171 | $828,529 |
| Total Liabilities And Equity | $2,185,875 | $1,532,105 | $1,560,637 | $1,476,772 | $948,604 |